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ABSTRACT: 
Background: 
Cardiovascular disease is a global epidemic; the prevalence is currently stable in the developed world but 
is on a rapid rise in the developing world particularly in Sub-Saharan Africa. It is the commonest cause of 
morbidity and mortality globally. Its victims are older in the developed world but younger in Africa where it 
affects mainly the productive age group. The morbidity is more than its mortality such that majority its 
victims are rendered unproductive and burdensome. The burden of the disease has shifted to the developing 
world particularly Sub-Saharan Africa. In 2002 over 80% of CVD associated mortality occurred in the 
developing world, and a victim is many times more likely to die than in the developed world. Fortunately as 
there is no smoke without fire, cardiovascular disease is preceded by certain modifiable and non-
modifiable risk factors which can be identified and corrected before a full blown disease occurs.
Method: 
This is a detailed search of existing literature and on-line database on the subject. A narrative review of the 
selected literature was then done to provide concise and current information on the subject. 
Conclusion:
Cardiovascular disease is preventable. Governments at all levels must as a matter of urgency set up 
workable programmes to combat this scourge at the level of the risk factors. Interventions at the primary, 
secondary and tertiary levels must be implemented fully. Medical staffs must be trained at all levels to 
identify risk factors and treat them early.  
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Introduction:
Cardiovascular diseases (CVD) are diseases of the 
heart and blood vessels. They
 
Current epidemiologic predictions show that the 
world is heading for a cardiovascular disease 
pandemic. A recent cohort study reports that over 
90% of the general population have a CVD risk 
factor;  more than 70% of these individuals had 
2
multiple risk factors . In 2002, cardiovascular 
disease was estimated to have been responsible for 
 are a continuum that 
begin with the presence of risk factors, which if 
untreated progresses to target organ damage and 
1end-organ failure .
29% of deaths and 43% of morbidity 
world; it is currently the leading cause of death and 
3has been for over 20 years .The global burden far 
exceeds that of its death toll, affecting an estimated 
128 million people, or nearly 8 times the number for 
mortality. Thus, the greater burden is attributable to 
4,5nonfatal events and their long-term consequences . 
In the developing world, the probability of 
morbidity and mortality is higher than in developed 
6world .
Currently the prevalence is stable in the developed 
world but is on a rapid rise in Africa where it has also 
across the 
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7reached epidemic proportions . Several African 
countries including Nigeria have reported rising 
incidences. Many have sought to explain this as a 
phenomenon of epidemiological transition (Africa 
in stage 4 or 5 presently) and the increasing 
8,9
westernization of lifestyles .
Based upon statistics by the World Health 
Organization, approximately 80% of deaths caused 
by cardiovascular disease in 2003 occurred in 
3developing countries . It is the leading cause of 
death in all regions except for Sub-Saharan Africa; 
however when the analysis extends beyond adults 
aged 30 years and older, it is commonest cause of 
10death in all regions .
Compounding this problem, these deaths typically 
occur ten to fifteen years earlier than in developed 
countries thus reducing workforce capacity and 
10potential for economic growth . As the epidemic 
advance, the social gradient also reverses with the 
poor becoming the most vulnerable victims in both 
10developed and developing countries .
The development is promoted by its risk factors e.g. 
dyslipidemia, hypertension, diabetes, obesity, 
sedentary lifestyle, smoking. These risk factors are 
independently associated with cardiovascular 
disease and are common among adults. The 
identification of these risk factors and the 
implementation of control strategies can and have 
contributed to the fall in mortality rates observed in 
10
many industrialized nations  .  
Cardiovascular disease Risk factors:
Clinically and epidemiologically, they are divided 
into 2 broad groups i.e. modifiable and non-
modifiable risk factors. They can also be grouped 
as major or minor depending on strength of 
association. The modifiable risk factors include 
hypertension, diabetes, smoking, obesity, 
8-12
sedentary lifestyle, dyslipidemia  e.t.c. Non-
modifiable risk factors are age, gender, family 
history and genetic predisposition. Certain risk 
factors such as Human Immunodefiency Virus 
Infection, chronic parasitic infections, nutritional 
deficiencies etc are also linked to CVD and are 
prevalent in Sub-Saharan Africa. The Framingham 
Heart Study has established the independent 
impact of these risk factors in the development of 
13
cardiovascular disease . Exposure to antecedent 
major risk factors is very common among those 
who develop the disease. Thus emphasizing the 
importance of considering all major risk factors in 
determining risk and in attempting to prevent 
11,12clinical disease .
Hypertension: 
Hypertension is a common and important major and 
modifiable risk factor for cardiovascular 
11,14. 
disease. According to WHO report of 2002, it is 
the third most important contributor to global 
disease burden among the six chief risk factors of 
underweight, unsafe sex, hypertension, unsafe 
water, tobacco and alchohol abuse; it is also the 
6,9,15
leading cause of global mortality . In Nigeria, it is 
the commonest cardiovascular disease risk factor 
16with a prevalence rate of 20-25% . It is the 
commonest cause of hospital admissions in tertiary 
17
medical institutions in Nigeria .   
Hypertension is a harbinger of cardiovascular 
disease and its risk factors,  it is usually clustered 
with other risk factors e.g obesity, insulin 
14,18-2resistance, diabetes and dyslipidaemia  
Lowering blood pressure reduces morbidity and 
mortality for hypertension of all degrees and even in 
20
high-risk normotensive individuals . The 
relationship between blood pressure and risk of 
CVD event is consistent, continuous and 
independent of other risk factors. For individuals 
40- 70 years of age, each increment of 20mmHg in 
systolic BP or 10 mmHg in diastolic BP doubles the 
risk of CVD across the entire blood pressure range 
21,22from 115/75 to 185/115 mmHg . People of 
African descent tend to have higher blood pressure 




  This is a major and modifiable risk factor; it is a 
significant predictor of endothelial dysfunction and 
atherosclerosis in all populations. A fifth of global 
stroke events and about 56% of global heart disease 
 23. are attributable dyslipiderma  It is one of the top 3 
causes of mortality in the industrialized world and is 
associated with significant co-morbidities such as 
23,24
diabetes, obesity and hypertension . In particular, 
high levels of total cholesterol and low levels of 
HDL have been extensively studied and found to be 
associated with increased rates of cardiovascular 
disease and so are used to calculate CVD risk scores 
13,19,24e.g. the Framingham risk score .
Obesity: 
This has reached epidemic proportions globally 
with more than one billion adults being overweight 
25.and at least 300 million being clinically obese   
Obesity is an intriguing and paradoxical CVD risk 
in developing countries. This is because in regions 
such as Sub-Saharan Africa, epidemics of famine 
that culminate in malnutrition are believed to 
predominate. However, urbanization of some 
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regions has in fact induced higher obesity rates. The 
prevalence of obesity varies in different parts of 
Nigeria. For instance, Maiduguri has an overall 
prevalence of 2% while the urban working class of 
Ibadan has a prevalence of obesity as high as 
8,26 
24.5%. Abubakari et al found a prevalence of 
27about 10% across West Africa . Mortality is an 
exponential function of increasing body weight, the 
risk of coronary heart disease (CHD) doubles with 
body mass index (BMI) greater than 25 and 
28,29increases nearly fourfold when it is above 29 .
The risk of developing type 2 diabetes also 
increases with weight such that individuals with a 
BMI above 35 have a 40-fold higher risk of 
developing diabetes when compared to non-obese 
30.  individuals  It is a major and modifiable risk 
factor.
Diabetes mellitus: 
The prevalence of diabetes in adults worldwide was 
estimated to be 4.0% in 1995 and is expected to rise 
31. 
to 5.4% by the year 2025  The major part of this 
increase will occur in developing countries. Thus, 
by the year 2025, 75% of people with diabetes will 
reside in developing countries, as compared with 
31
62% in 1995 . A 2008 review found an increase in 
the prevalence of diabetes in Nigeria and Ghana. 
From 1963 to 1998, the prevalence rose from 0.2% 
to 6.3% of the adult Ghanaian population while 
amongst Nigerians, the prevalence rose from 
321.65% to 6.8% from 1985 to 2000 . Across Africa, 
the majority of people with diabetes are in the age 
range of 45-64years unlike in the West where they 
3 1
are older . Diabetes is an established 
major/modifiable risk factor for the development 
11,12,33
of CVD . A person with diabetes has a 2-4 fold 
greater risk of developing CVD compared with one 
without diabetes. cardiovascular disease is also the 
leading cause of morbidity and mortality for those 
33
living with diabetes .
Sedentary lifestyle: 
This is a modifiable risk factor with an adverse 
impact on blood glucose levels, blood pressure and 
lipid profiles raising the risk of a cardiovascular 
34event twofold . Independent of its impact on 
weight; regular exercise has favourable effects on 
glucose control, blood pressure, serum lipids and 
35,36
fitness levels . Poor fitness in young adults is 
associated with the development of cardiovascular 
risk factors. These associations involve obesity and 
37may be modified by improving fitness . Sedentary 
lifestyle with its associated risk is increasing 
becoming rampant in Africa due to rural to urban 
migration.  Injury to endothelium causes endothelial dysfunction
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Smoking: 
Worldwide the lowest smoking prevalence for both 
men and women is in Africa, while the highest 
prevalence for men is in Eastern Europe (>60%) and 
for women in Central Europe and parts of South 
38
America . The greatest increases in smoking 
prevalence over the next decade are expected to 
occur in Africa and the Middle East. Recent 
evidences suggest that smoking promotes other co-
morbidities such as lung cancer; it reduces 
immunity and causes endothelial dysfunction, 
h y p e r t e n s i o n ,  t h r o m b o e m b o l i s m  a n d  
atherosclerosis by release of the several noxious 
39  
substances . Smoking is a major and modifiable 
risk factor.
Age and Gender: 
The risk for cardiovascular disease increases steeply 
with advancing age in men and women. Historically, 
men have had higher cardiovascular related 
39
mortality rates than women . However, CVD is still 
the leading cause of mortality in women, being 
responsible for a third of all deaths of women 
worldwide and half of all deaths of women over 50 
39
years of age in developing countries . Some 
retrospective analyses suggest that there are some 
clinically relevant differences between women and 
men in terms of prevalence, presentation, 
management and outcomes of the disease. However 
not much is known about why cardiovascular 
disease affects women and men differently. In 
Africa, the population is growing older hence the 
increase in cardiovascular disease rates. 
Pathophysiology of Cardiovascular disease: 
Endothelial dysfunction resulting from endothelial 
injury inflicted by the  risk factors appears to be the 
common pathway for the development of 
40cardiovascular disease . The endothelium is 
susceptible to the shear stress and inflammation in 
the presence of risk factors. Preponderance of these 
risk factors promotes migration of inflammatory 
cells from the circulation and the subendothelial 
space into the endothelial layer of the blood vessel. 
This results in chronic inflammation, intima 
scarring and atherosclerosis which manifests with 
certain symptoms and signs depending on the 
vascular bed affected.
9
Treatment of Cardiovascular disease: 
Smoking: Quitting smoking is associated with a 
substantial reduction in risk (36% reduction in 
crude relative risk) of all-cause mortality among 
41
patients with CHD . Patients who stop smoking 
can expect an increase of up to 30 percent in their 
42
HDL-C levels . Smoking cessation results in 60% 
reduction of CHD risk by 3 years; about half of that 
benefit occurs  3-6months after quitting.
Hypertension: 
The health goal of treatment is the reduction of 
cardiovascular and renal morbidity and mortality. 
The primary focus is on achieving the blood 
pressure goal. Treating blood pressure to targets 
that are <140/90 mmHg is associated with a 
decrease in CVD complications. In patients with 
hypertension and diabetes or renal disease, the 
43,44
blood pressure goal is <130/80 mmHg . 
Pharmacologic therapy must take into cognisance 
other co-morbidity present in the patient. 
Combination therapy is often recommended using 
the first line drugs i.e. diuretics, Angiotensen 
Converting enzyme inhibitors, angiotensen 
receptor blockers, beta blockers and calcium 
channel blockers.
The JNC 7 report also recommends lifestyle 
modification for all patients with hypertension and 
45prehypertension, these modifications include : 
- Reducing dietary sodium to less than 2.4 g per 
day;
- Increasing exercise to at least 30 minutes per 
day, four days per week; 
- Limiting alcohol consumption to 21 units or 
less per week for men and 14 units or less per 
week for women. ; 
- Following the Dietary Approaches to Stop 
Hypertension (DASH) eating plan (high in 
fruits, vegetables, potassium, calcium, and 
magnesium; low in fat and salt) and
- Achieving a weight loss goal of 4.5 kg or more  
Diabetes: 
The treatment of diabetes mellitus involves 
multiple goals (glycaemia, lipids, BP). The United 
Kingdom Prospective Diabetes Study (UKPDS) 
provides ample evidence that glycaemia control is 
pa ramount  in  r educ ing  mic rovascu la r  
complications. Focusing on glucose alone does not 
46
manage patients with diabetes mellitus optimally . 
Oral agents should always be combined with 
lifestyle modification, including regular exercise 
and attention to both individual food choices and 
overall caloric intake to further optimize glycaemia 
control. Often pharmacotherapy with at least one 
lipid-lowering agent is also required. Blood 
pressure control often requires the use of 
combination therapy in patients with diabetes. 
Clinical data support use of an ACE inhibitor as 
first-line therapy for the prevention of 
microalbuminuria in patients with diabetes and 
hypertension. Low-dose aspirin is appropriate for 
patients over age 45 for primary prevention of 
cardiovascular disease.  
Dyslipidaemia: 
Atherogenic dyslipidaemia consists of abnormal 
levels of triglycerides, LDL-C particles, and low 
HDL-C levels. LDL-C is the primary target of 
therapy. Statins are recommended as first-line 
agents for lowering LDL-C levels and reducing the 
23
risk of CHD .
Regular Exercise: 
The AHA/NHLBI recommends 60 minutes of 
continuous or intermittent aerobic activity 
(preferably brisk walking) daily to promote or 
maintain weight loss. Walking should be 
supplemented by jogging, swimming, biking, 
golfing, team sports, resistance training, use of a 
treadmill or other simple exercise equipment, or 
multiple 10-15-minutes sessions of activity (e.g. 
walking breaks at work, gardening, or housework). 
Patients should also be advised to limit television 
25,33-37
viewing and other sedentary activities .  
Weight loss and Healthy diet: 
Effective weight loss requires a combination of 
caloric restriction, physical activity, and 
motivation. The glycaemic load of a diet influences 
the risk of CVD, particularly in people who are 
overweight and obese. Rapidly absorbed 
carbohydrates such as refined grains and sugar and 
sugar-sweetened beverages that induce have a high 
glycaemic index. Replacing these with unsaturated 
fats and/or protein and whole grains can help 
25-45prevention and improve overall health . Daily 
diet should be low in saturated fats, trans fats, 
cholesterol, sodium, and simple sugars. In addition, 
there should be ample intake of fruits, vegetables, 
and whole grains. The intake of fish should also be 
encouraged.   
Conclusion: 
2-4
Cardiovascular disease is a global epidemic ; the 
prevalence is currently stable in the developed 
6-10
world but is on a rapid rise in Sub-Saharan Africa . 
It is the commonest cause of morbidity and 
6mortality globally . Its victims are older in the 
developed world but younger in Africa where it 
47
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affects mainly the productive age group. The 
morbidity is more than its mortality such that most 
of its victims live but are rendered unproductive 
6-10
and burdensome . The burden of the disease has 
shifted to the third world. In 2002 over 80% of 
CVD associated mortality occurred in the 
3 
developing world and a victim is many times  than 
3,6in the developed world . Fortunately as there is no 
smoke without fire, cardiovascular disease is 
preceded by certain modifiable and non-modifiable 
risk factors which can be identified and corrected 
before a full blown cardiovascular disease with its 
10-15attendant complications occurs . Government 
must as a matter of urgency set up workable local 
programmes to combat this scourge at the level of 
the risk factors. Interventions at the primary, 
secondary and tertiary levels must be implemented 
fully. Medical staffs must be trained at all levels to 
identify risk factors and treat them early.  
 Major CVD risks and appropriate interventions
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